Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 6/20 | 0.33 |
| ▸ | CPA1 | P15085 | 1/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.33 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.33 |
| ▸ | WDR5 | P61964 | 1/20 | 0.31 |
| ▸ | TYR | P14679 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30268858 | 0.84 | — | — | |
| SCHEMBL22185207 | 0.81 | — | — | |
| SCHEMBL19789308 | 0.81 | KDM5A (0.32) | KDM5A | |
| SCHEMBL30291508 | 0.80 | KDM5A (0.35) | KDM5A | |
| SCHEMBL30268892 | 0.80 | — | — | |
| SCHEMBL30268898 | 0.79 | PSEN1 (0.33) | — | |
| SCHEMBL30268927 | 0.77 | KDM5B (0.49) | KDM5A | |
| SCHEMBL19789327 | 0.77 | BRD4 (0.34) | — | |
| SCHEMBL19789443 | 0.77 | BRD4 (0.34) | — | |
| SCHEMBL30268856 | 0.76 | KDM5B (0.39) | KDM5ATYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4146645-B1 | 3-AZABICYCLO(3.1.0)HEXANE DERIVATIVES HAVING KDM5 INHIBITORY ACTIVITY AND USE THEREOF | ONO PHARMACEUTICAL CO (JP) | 2025-06-25 | — | — | EP | disclosed |
| US-20250171434-A1 | SEC61 INHIBITORS AND USE THEREOF | ENODIA THERAPEUTICS SAS (FR) | 2025-05-29 | — | — | US | disclosed |
| EP-4486451-A1 | SEC61 INHIBITORS AND USE THEREOF | Kezar Life Sciences, Inc. (US) | 2025-01-08 | — | — | EP | disclosed |
| WO-2024233665-A1 | COMPOUNDS AND THEIR USE AGAINST CANCER | TANGO THERAPEUTICS, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| CN-115461338-B | 3-azabicyclo (3.1.0) hexane derivatives having KDM5 inhibitory activity and uses thereof | 小野药品工业株式会社 | 2024-02-20 | — | — | CN | disclosed |
| WO-2023216910-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUND AS USP1 INHIBITOR | 苏州浦合医药科技有限公司 | 2023-11-16 | — | — | WO | disclosed |
| CN-117003757-A | Substituted bicyclic heteroaryl compounds as USP1 inhibitors | 苏州浦合医药科技有限公司 | 2023-11-07 | — | — | CN | disclosed |
| WO-2023164250-A1 | SEC61 INHIBITORS AND USE THEREOF | KEZAR LIFE SCIENCES (US) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023164250-A1 | SEC61 INHIBITORS AND USE THEREOF | KEZAR LIFE SCIENCES (US) | 2023-08-31 | — | — | WO | disclosed |
| EP-4146645-A1 | 3-AZABICYCLO(3.1.0)HEXANE DERIVATIVES HAVING KDM5 INHIBITORY ACTIVITY AND USE THEREOF | ONO Pharmaceutical Co., Ltd. (JP) | 2023-03-15 | — | — | EP | disclosed |
| CN-115461338-A | 3-azabicyclo (3.1.0) hexane derivatives having KDM5 inhibitory activity and uses thereof | 小野药品工业株式会社 | 2022-12-09 | — | — | CN | disclosed |
| US-9284350-B2 | IAP BIR domain binding compounds | PHARMASCIENCE INC. (CA) | 2016-03-15 | — | — | US | disclosed |
| US-20130040892-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | PHARMASCIENCE INC. (CA) | 2013-02-14 | — | — | US | disclosed |
| US-20050153964-A1 | Pyrimidone compounds which are inhibitors of the enzyme Lp-PLA2; use in treating atheroscelerosis | GLAXO GROUP LIMITED (GB) | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040892-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | BIRC5, BIRC2, BIRC3 | KDM5A 3357/4885CPA1 1405/4885CPB2 3960/4885 |
| US-20050153964-A1 | Pyrimidone compounds which are inhibitors of the enzyme Lp-PLA2; use in treating atheroscelerosis | LYPLAL1, PLA2G12A, ENPP2 | KDM5A 2576/4885CPA1 92/4885CPB2 197/4885 |
| US-20250171434-A1 | SEC61 INHIBITORS AND USE THEREOF | SEC61B, SEC61A1, SEC61G | KDM5A 4745/4885CPA1 1901/4885CPB2 1350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.